藥明康德(603259.SH)認繳200萬美元投資基金份額
格隆匯8月22日丨藥明康德(603259.SH)公佈,北京時間2019年8月21日,公司全資子企業WuXiPharmaTech Healthcare Fund I L.P.(“WuXi Fund I”)與Mission Bay Capital III, L.P.(“投資基金”)簽署Subscription Agreement,約定由WuXi Fund I認繳200萬美元的投資基金份額,佔已募集投資基金份額的3.3%。截至公告日,WuXi Fund I尚未實繳出資,後續WuXi Fund I將以自有資金根據認購協議及普通合夥人的出資要求履行出資義務。
投資基金預計募集總額不超過8500萬美元,WuXi Fund I本次認繳200萬美元后,投資基金已募集6060.606萬美元。基金擬投資領域生命科學領域涉及治療產品、診斷產品、合成生物學和研究工具的新創企業。
得益於Crawford博士創建的Mission Bay Capital BioLabs生命科學企業孵化器,投資基金相較於傳統的風險投資基金能更早參與項目投資。因為在投資以前,被投資企業通常已在孵化器內經營6至18個月,從而可以為投資基金帶來早期項目來源以及對目標項目進行深入盡職調查的機會。通過成為投資基金的投資人,藥明康德有機會獲取投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.